Screener
Syndax Pharmaceuticals SNDX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized; 88,543,881 and 87,405,979 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 9 | 9 |
| Additional paid-in capital | 1,590,855 | 1,570,749 |
| Accumulated other comprehensive gain | 11 | 452 |
| Accumulated deficit | (1,549,253) | (1,506,580) |
| Total stockholders’ equity | 41,622 | 64,630 |
| Total liabilities and stockholders’ equity | $472,668 | $529,706 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's total equity?
- Syndax Pharmaceuticals (SNDX) reported total equity of $41.62M in Q1 2026.
- How has Syndax Pharmaceuticals's total equity changed year-over-year?
- Syndax Pharmaceuticals's total equity decreased by 80.6% year-over-year, from $215.06M to $41.62M.
- What is the long-term trend for Syndax Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total equity has grown at a -23.8% compound annual growth rate (CAGR), from $252.19M to $64.63M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Syndax Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude